Brentuximab vedotin plus lisaftoclax for CD30+ CTCL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two drugs for people with a specific type of skin lymphoma. Brentuximab vedotin targets a protein called CD30 on lymphoma cells, and lisaftoclax helps destroy those cells. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have mycosis fungoides or primary cutaneous anaplastic large cell lymphoma (pcALCL) that has not been treated with chemotherapy before.
- Your lymphoma cells have the CD30 protein (confirmed by a skin biopsy).
- You have had at least one prior treatment (like skin-directed therapy or radiation) for your lymphoma.
- You are able to get up and take care of yourself most of the day (ECOG score 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing new treatment plans based on the genetic type of your cutaneous T-cell lymphoma (CTCL). It's for people whose CTCL did not respond well to standard skin treatments.
This trial tests whether the drug brentuximab vedotin can help prevent lymphoma from coming back after a stem cell transplant. It is for people with a specific type of skin lymphoma called mycosis fungoides.
This Phase 2 trial studies whether giving very low-dose total-skin electron beam radiation at the same time as brentuximab vedotin can control mycosis fungoides (a lymphoma that affects the skin). It’s for people whose disease has returned or hasn’t responded to prior treatment, especially if the tumor marker CD30 is present.
This trial tests a combination of two targeted drugs, chidamide and brentuximab vedotin, for people with a type of T-cell lymphoma that has the CD30 protein. It is for patients who are older or not healthy enough for standard chemotherapy, and whose cancer has come back or not responded to previous treatment.
This Phase 2 trial studies the combination of brentuximab vedotin and bendamustine in people whose follicular lymphoma has come back or did not respond. It aims to shrink the lymphoma and improve outcomes after at least one prior treatment.
This trial tests a new drug, lisaftoclax (APG-2575), for people with certain slow-growing B-cell lymphomas. It's for those who haven't had treatment or can't take standard targeted therapy, or who had a targeted therapy but it didn't work well or caused serious side effects.
Hear when a new Cutaneous T-Cell Lymphoma/Mycosis Fungoides trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.